March 28, 2016April 4, 2016

Drug Company Collaboration for IPF Therapy Leads to Positive Results; Phase 1 Trial to Launch in 2017

Synairgen recently announced positive results from its collaboration with Pharmaxis in their goal to develop a lysyl oxidase type 2 enzyme (LOXL2) inhibitor as an innovative treatment for the life-threatening lung disease ... Read more

March 15, 2016May 13, 2016

New Gene Study to Determine Why Some People Are More Prone to Developing Asthma

Asthma, News

New research from the University of Southampton in England is set to expand scientists’ knowledge about why some people are more prone to develop asthma by analyzing a gene called ADAM33 – typically ... Read more